Business
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
Expansion of RADR® platform adds new AI capabilities for the automated identification of new and effective combination therapy regimens for immune checkpoint
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nExpansion of RADR® platform adds new AI capabilities for the automated identification of new and effective combination therapy regimens for immune checkpoint inhibitors (ICI)\n\n\n\nAdditional functionality includes the creation and testing of molecular signatures of ICI response and resistance with a highly scalable, machine-learning based system designed to improve ICI clinical trial outcomes\n\n\n\nWorldwide, ICIs generated $41.5 billion in annual sales in 2022 and are projected to reach $67.8 billion by 2025, according to GlobalData\n\n\n\nFuture ICI growth hinges on new approvals for novel ICI candidates and biomarker-guided strategies to position ICI combination regimens in new cancer indications, in earlier lines of treatment, and in historically difficult to treat populations\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced a substantial increase in the power and capabilities of RADR® focused on improving the drug development process for immune checkpoint inhibitors (ICIs). These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy. Since gaining regulatory approval in 2011, ICIs have improved the lives of tens of thousands of cancer patients as either monotherapies, and more recently, in combination regimens with other therapies. The success of ICIs has resulted in multiple competing ICI molecules, often from the same class, in overlapping cancer indications. Additionally, recent clinical trial failures reveal headwinds to the desired expansion of ICIs for a broader range of cancers and patient groups. Currently, there are over 5,200 ongoing clinical trials involving ICIs, many of these lacking adequate biomarker strategies or guidance from AI enabled approaches to optimize the selection of patient responder populations.\n\n\n\"We are expanding the functionality of our RADR® AI platform in ways that aim to solve the very meaningful and important challenges of future checkpoint inhibitor development. We initially began this effort by identifying meaningful combinations with checkpoint inhibitors that might be the mo...